Perspectives on development of a combination pharmacogenomic diagnostic and drug product.
This perspective outlines the challenges to joint development of a predictive genetic diagnostic with a drug to enhance the efficacy or safety of therapy with the targeted drug. Joint development requires a discovery approach to identify the genetic marker(s), followed by a replication or validation process confirming the clinical utility of the genetic marker(s) in predicting response to the targeted drug. The promise of overcoming these hurdles is that combined use of the genetic diagnostic linked to the drug provides additional scientific information to assist the clinician in their choice of therapeutic interventions on a patient-by-patient basis.
McCamish
Mark
M
Perlegen Sciences, Inc., 2021 Stierlin Court, Mountain View, CA 94043, USA. Mark_McCamish@perlegen.com
Izumi
Raquel
R
D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D019411:Clinical Laboratory Techniques / Q000639:trends*; D004358:Drug Therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D014644:Genetic Variation; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*; D010600:Pharmacology / Q000639:trends*
D002317:Cardiovascular Agents